YO Ab Screen, IFA, Serum

Sample type: Serum
Negative
A negative result in the YO Ab Screen, IFA, Serum test indicates the absence of anti-Yo antibodies, suggesting that the patient's neurological symptoms are unlikely related to paraneoplastic cerebellar degeneration (PCD) associated with ovarian or breast cancer. However, it's important to consider other potential causes of the symptoms, as a negative result does not completely rule out all paraneoplastic syndromes or other neurological disorders. Given the specific nature of this test, further diagnostic evaluations, including additional antibody tests and comprehensive neurological assessments, may be necessary. The test result should be interpreted within the broader context of the patient's overall clinical presentation, symptoms, and medical history to ensure accurate diagnosis and appropriate treatment planning.
Positive
A "POSITIVE" result on a Yo Antibody Screen (also known as Anti-Yo or PCA-1) using the Immunofluorescence Assay (IFA), Serum, performed by Quest Diagnostics, indicates that antibodies against Yo antigens were detected in your blood. These Yo antibodies are associated with a specific type of paraneoplastic syndrome, a group of rare disorders that occur when an immune response against cancer affects the nervous system, causing neurological symptoms. In particular, Anti-Yo antibodies are most commonly linked to paraneoplastic cerebellar degeneration, which can lead to rapid onset of movement disorders, coordination problems, and other cerebellar symptoms. This condition is often associated with certain types of cancer, most notably ovarian and breast cancer in women, and less commonly in other types of cancer.
Fluorescence noted
A result of "Fluorescence noted (Abnormal)" on a Yo AB Screen, IFA (Immunofluorescence Assay), Serum test by Quest Diagnostics indicates that the test has detected the presence of anti-Yo antibodies in the serum, which is considered an abnormal finding. Anti-Yo antibodies are a type of autoantibody associated with paraneoplastic cerebellar degeneration (PCD), a rare disorder that can occur as a paraneoplastic syndrome. Paraneoplastic syndromes are a group of disorders that arise from an immune system response to a malignancy (cancer) elsewhere in the body, leading to symptoms in parts unrelated to the tumor itself. In the case of anti-Yo antibodies, the immune response is typically associated with certain types of cancer, most commonly ovarian or breast cancer in women, although it can also be related to other types of cancer. The presence of these antibodies suggests that the body's immune system is reacting to cancer by producing antibodies that mistakenly attack the cerebellum, a part of the brain that controls coordination and balance, leading to neurological symptoms such as difficulty walking, speaking, and swallowing. However, if the accompanying Western Blot result was negative it introduces complexity into the interpretation. The Western Blot is a more specific test used to confirm the presence of antibodies identified through screening tests like IFA. A negative Western Blot result might suggest that, despite the initial abnormal IFA finding, there is not enough specific evidence to confirm the presence of anti-Yo antibodies when using this more precise method. In clinical practice, these results together suggest a need for cautious interpretation. It might indicate a potential false positive in the IFA test, or the Western Blot might not have been sensitive enough to detect the antibodies present at low levels. It's crucial for the healthcare provider to consider these results in the context of the patient's symptoms, clinical history, and the possibility of an underlying malignancy. Further evaluation and monitoring might be necessary to understand the significance of these findings fully and to decide on the appropriate next steps in diagnosis and treatment.

The YO Ab Screen, IFA (Immunofluorescence Assay), Serum test is a crucial diagnostic marker used primarily in neurology and oncology to detect paraneoplastic neurological syndromes, especially paraneoplastic cerebellar degeneration (PCD) associated with ovarian and breast cancers. This test identifies anti-Yo antibodies, indicative of an autoimmune response where the body's immune system mistakenly targets its own central nervous system tissues in reaction to cancer. The use of IFA, a highly sensitive technique, allows for the precise detection of these antibodies. A positive result can be an early indicator of an underlying malignancy, often before the cancer is clinically identifiable. This test is instrumental in guiding the diagnosis and management of PCD and aids in the early detection and treatment of associated cancers. The YO Ab Screen, IFA, Serum test exemplifies the intersection of neurology and oncology in modern diagnostics, emphasizing the significance of specialized testing in early cancer detection and the management of its neurological complications.

YO Ab Screen, IFA, Serum
Healthmatters dashboard showing biomarker trend graph

Every lab result you’ve ever had, charted and explained.

Healthmatters is a tracker for your lab results. Upload a report from any lab, any country — every marker charted and explained.

Start with my report →
Beyond YO Ab Screen, IFA, Serum — 10,000+ markers explained
One YO Ab Screen, IFA, Serum result tells you where you are. Your history tells you where you’re heading. Upload your past lab reports and see this marker — and every marker on them —every marker charted against your own lab’s ranges.
Start with this report →
Healthmatters timeline preview showing biomarker trends over time
Clinical Sources & References

All our content is backed by peer-reviewed studies, academic research, and trusted medical sources. We’re committed to accuracy and transparency — see our editorial policy for details.

Article Review Log
Written by Healthmatters Editorial Team
Healthmatters Lifetime Plan

Pay $250. Track your health forever

One payment. No renewals. Yours for life.

10,000+ biomarkers explained · trends over time

See other plans →
Secure checkout via Stripe · GDPR & HIPAA
We accept results from any lab
LabCorp Quest Diagnostics Genova Diagnostics DUTCH Test Doctor's Data Vibrant America ZRT Laboratory Cyrex Labs + any other lab

What members are saying

★★★★★ 10,000+ happy members
★★★★★

"Watching my numbers move over the years — instead of forgetting last time's results — completely changed how I manage my health."

Daniel
Member since 2022
★★★★★

"Living across several countries made keeping my lab results organized a real challenge. Healthmatters brought my results from the USA, Spain, and Germany together — 20 years of history, with long-term trends instead of scattered reports."

Ben
Member since 2021 · tracks across countries
★★★★★

"Standard lab ranges are too wide for how I practice — 'normal' isn't optimal. I set my own bands, so a client sees yellow before a marker goes officially out of range. That's the conversation I want to be having."

Dr. Alexandra
Functional medicine · 6 yrs on Pro